These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11962679)

  • 21. Genitourinary cancer.
    Hudes GR; Ozols RF; Schilder RJ
    Cancer Chemother Biol Response Modif; 1991; 12():509-48. PubMed ID: 1718377
    [No Abstract]   [Full Text] [Related]  

  • 22. Chemotherapy with FUDR in the management of metastatic renal cell carcinoma.
    Aveta P; Terrone C; Neira D; Cracco C; Rocca Rossetti S
    Ann Urol (Paris); 1997; 31(3):159-63. PubMed ID: 9251833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin.
    Corral DA; Sella A; Pettaway CA; Amato RJ; Jones DM; Ellerhorst J
    J Urol; 1998 Nov; 160(5):1770-4. PubMed ID: 9783949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.
    Wilkinson MJ; Frye JW; Small EJ; Venook AP; Carroll PR; Ernest ML; Stagg RJ
    Cancer; 1993 Jun; 71(11):3601-4. PubMed ID: 8490909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The therapeutic index of cytotoxic chemotherapy depends upon circadian drug timing.
    Von Roemeling R
    Ann N Y Acad Sci; 1991; 618():292-311. PubMed ID: 2006791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of genitourinary tumours with cis-dichlorodiammineplatinum(II): experience in 250 patients.
    Merrin CE
    Cancer Treat Rep; 1979; 63(9-10):1579-84. PubMed ID: 574057
    [No Abstract]   [Full Text] [Related]  

  • 27. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.
    Wiseman LR; Spencer CM
    Drugs Aging; 1998 Apr; 12(4):305-34. PubMed ID: 9571394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump.
    Damascelli B; Marchianò A; Spreafico C; Lutman R; Salvetti M; Bonalumi MG; Mauri M; Garbagnati F; Del Nero A; Comeri G
    Cancer; 1990 Jul; 66(2):237-41. PubMed ID: 2142443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study.
    Falcone A; Cianci C; Ricci S; Brunetti I; Bertuccelli M; Conte PF
    Cancer; 1993 Jul; 72(2):564-8. PubMed ID: 8319188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circadian timing of cancer chemotherapy.
    Hrushesky WJ
    Science; 1985 Apr; 228(4695):73-5. PubMed ID: 3883493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination chemotherapy (CISCA) for advanced urinary tract carcinoma. A preliminary report.
    Sternberg JJ; Bracken RB; Handel PB; Johnson DE
    JAMA; 1977 Nov; 238(21):2282-7. PubMed ID: 578848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of multidrug resistance in tumors of the genitourinary tract.
    Theyer G; Hamilton G
    Urology; 1994 Dec; 44(6):942-50. PubMed ID: 7985331
    [No Abstract]   [Full Text] [Related]  

  • 35. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.
    Muggia FM
    Semin Oncol; 2004 Dec; 31(6 Suppl 14):17-24. PubMed ID: 15726530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of liposomal doxorubicin in advanced gynecologic cancers.
    Israel VP; Garcia AA; Roman L; Muderspach L; Burnett A; Jeffers S; Muggia FM
    Gynecol Oncol; 2000 Aug; 78(2):143-7. PubMed ID: 10926793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
    Fleming GF; Fowler JM; Waggoner SE; Copeland LJ; Greer BE; Horowitz I; Sutton G; Schilder RJ; Fracasso PM; Ball HG; McGuire WP
    J Clin Oncol; 2001 Feb; 19(4):1021-9. PubMed ID: 11181665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Toxicity and efficacy of chemotherapy dependent on circadian time of cytostatic drug administration].
    Zuchowska-Vogelgesang B; Pernal J; Zemełka T
    Przegl Lek; 1996; 53(12):870-3. PubMed ID: 9163011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of the therapeutic index of floxuridine by its circadian infusion pattern.
    von Roemeling R; Hrushesky WJ
    J Natl Cancer Inst; 1990 Mar; 82(5):386-93. PubMed ID: 2137540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The circadian timing system in clinical oncology.
    Innominato PF; Roche VP; Palesh OG; Ulusakarya A; Spiegel D; Lévi FA
    Ann Med; 2014 Jun; 46(4):191-207. PubMed ID: 24915535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.